Perioperative Levosimendan Infusion in Patients With End-Stage Heart Failure Undergoing Left Ventricular Assist Device Implantation

被引:6
作者
Abdelshafy, Mahmoud [1 ,2 ,3 ]
Elsherbini, Hagar [4 ]
Elkoumy, Ahmed [1 ,2 ,5 ]
Simpkin, Andrew J. [6 ,7 ]
Elzomor, Hesham [1 ,2 ,5 ]
Caliskan, Kadir [3 ]
Soliman, Osama [1 ,2 ,8 ]
机构
[1] Galway Univ Hosp, Hlth Serv Execut, Discipline Cardiol, Saolta Healthcare Grp, Galway, Ireland
[2] Natl Univ Ireland Galway NUIG, CORRIB Core Lab, Galway, Ireland
[3] Al Azhar Univ, Dept Cardiol, Cairo, Egypt
[4] Erasmus MC Univ Med Ctr, Dept Cardiol, Rotterdam, Netherlands
[5] Al Azhar Univ, Islamic Ctr Cardiol & Cardiac Surg, Cairo, Egypt
[6] Natl Univ Ireland Galway, Sch Math & Stat Sci, Galway, Ireland
[7] Natl Univ Ireland Galway, Insight Ctr Data Analyt, Galway, Ireland
[8] CURAM Ctr Med Devices, Galway, Ireland
关键词
levosimendan; LVAD; right-sided heart failure; inotropes; mechanical circularity support; heart failure;
D O I
10.3389/fcvm.2022.888136
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Left ventricular assist device (LVAD) therapy has been instrumental in saving lives of patients with end-stage heart failure (HF). Recent generation devices have short-to-mid-term survival rates close to heart transplantation. Unfortunately, up to 1 in 4 patients develop a life-threatening right-sided HF (RHF) early post LVAD implantation, with high morbidity and mortality rate, necessitating prolonged ICU stay, prolonged inotropic support, and implantation of a right-ventricular assist device. Pre-operative optimization of HF therapy could help in prevention, and/or mitigation of RHF. Levosimendan (LEVO) is a non-conventional inotropic agent that works by amplifying calcium sensitivity of troponin C in cardiac myocytes, without increasing the intra-cellular calcium or exacerbating ischemia. LEVO acts as an inodilator, which reduces the cardiac pre-, and after-load. LEVO administration is associated with hemodynamic improvements. Despite decades long of the use of LVAD and more than two decades of the use of LEVO for HF, the literature on LEVO use in LVAD is very limited. In this paper, we sought to conduct a systematic review to synthesize evidence related to the use of LEVO for the mitigation and/or prevention of RHF in patients undergoing LVAD implantation.
引用
收藏
页数:6
相关论文
共 10 条
[1]   Clinical pharmacology of levosimendan [J].
Antila, Saila ;
Sundberg, Stig ;
Lehtonen, Lasse A. .
CLINICAL PHARMACOKINETICS, 2007, 46 (07) :535-552
[2]   Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure [J].
Bonios, Michael J. ;
Terrovitis, John V. ;
Drakos, Stavros G. ;
Katsaros, Fotis ;
Pantsios, Chris ;
Nanas, Serafim N. ;
Kanakakis, John ;
Alexopoulos, George ;
Toumanidis, Savvas ;
Anastasiou-Nana, Maria ;
Nanas, John N. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 159 (03) :225-229
[3]   Intermittent levosimendan infusion in ambulatory patients with end-stage heart failure: a systematic review and meta-analysis of 984 patients [J].
Elsherbini, Hagar ;
Soliman, Osama ;
Zijderhand, Casper ;
Lenzen, Mattie ;
Hoeks, Sanne E. ;
Kaddoura, Rasha ;
Izham, Mohamed ;
Alkhulaifi, Abdulaziz ;
Omar, Amr S. ;
Caliskan, Kadir .
HEART FAILURE REVIEWS, 2022, 27 (02) :493-505
[4]   The Effectiveness of Levosimendan on Veno-Arterial Extracorporeal Membrane Oxygenation Management and Outcome: A Systematic Review and Meta-Analysis [J].
Kaddoura, Rasha ;
Omar, Amr S. ;
Ibrahim, Mohamed Izham Mohamed ;
Alkhulaifi, Abdulaziz ;
Lorusso, Roberto ;
Elsherbini, Hagar ;
Soliman, Osama ;
Caliskan, Kadir .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2021, 35 (08) :2483-2495
[5]   Optimization with levosimendan improves outcomes after left ventricular assist device implantation [J].
Kocabeyoglu, Sinan Sabit ;
Kervan, Umit ;
Sert, Dogan Emre ;
Karahan, Mehmet ;
Aygun, Emre ;
Beyazal, Osman Fehmi ;
Unal, Ertekin Utku ;
Akin, Yesim ;
Demirkan, Burcu ;
Pac, Mustafa .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2020, 57 (01) :176-182
[6]  
Liberati A, 2009, BMJ-BRIT MED J, V339, DOI [10.1016/j.ijsu.2010.02.007, 10.1371/journal.pmed.1000097, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.b2535, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]
[7]   Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period [J].
Poelzl, Gerhard ;
Allipour Birgani, Shadab ;
Comin-Colet, Josep ;
Delgado, Juan F. ;
Fedele, Francesco ;
Garcia-Gonzales, Martin Jesus ;
Gustafsson, Finn ;
Masip, Josep ;
Papp, Zoltan ;
Stoerk, Stefan ;
Ulmer, Hanno ;
Vrtovec, Bojan ;
Wikstroem, Gerhard ;
Altenberger, Johann .
ESC HEART FAILURE, 2019, 6 (01) :174-181
[8]   Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices The EUROMACS (European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk Score [J].
Soliman, Osama I. I. ;
Akin, Sakir ;
Muslem, Rahatullah ;
Boersma, Eric ;
Manintveld, Olivier C. ;
Krabatsch, Thomas ;
Gummert, Jan F. ;
de By, Theo M. M. H. ;
Bogers, Ad J. J. C. ;
Zijlstra, Felix ;
Mohacsi, Paul ;
Caliskan, Kadir .
CIRCULATION, 2018, 137 (09) :891-906
[9]   Preoperative Treatment with Levosimendan in Candidates for Mechanical Circulatory Support [J].
Sponga, Sandro ;
Ivanitskaia, Ekaterina ;
Potapov, Evgenij ;
Krabatsch, Thomas ;
Hetzer, Roland ;
Lehmkuhl, Hans .
ASAIO JOURNAL, 2012, 58 (01) :6-11
[10]   Intermittent levosimendan treatment for late onset right ventricular failure in a patient supported with a left ventricular assist device [J].
Yalcin, Yunus C. ;
Caliskan, Kadir .
ARTIFICIAL ORGANS, 2020, 44 (05) :533-534